Medical Condition

atrial fibrillation

Total Trials

41

Recruiting Now

41

Trial Phases

Phase 3, Phase 2, Phase 4

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting over 33 million people worldwide and conferring a fivefold increased risk of stroke. Clinical trials in AF address three core problems: rhythm control (restoring and maintaining sinus rhythm), rate control (controlling heart rate in persistent AF), and stroke prevention (anticoagulation). The EAST-AFNET 4 trial established early rhythm control as superior to a rate-control strategy in reducing cardiovascular events, reshaping international guidelines.

Current trials evaluate non-vitamin K oral anticoagulants (NOACs) in underserved populations, pulse field ablation versus radiofrequency ablation (ADVENT trial showed non-inferiority), left atrial appendage occlusion devices (WATCHMAN FLX) versus NOAC therapy in patients with bleeding risk, and novel antiarrhythmic drugs with improved safety profiles. Digital health trials using smartwatch-detected AF episodes are emerging as enrollment and monitoring tools.

CHA₂DS₂-VASc score determines anticoagulation eligibility; prior ablation history and type of AF (paroxysmal, persistent, long-standing persistent) determine eligibility for rhythm control trials.

Frequently Asked Questions — atrial fibrillation Clinical Trials

How many clinical trials are currently recruiting for atrial fibrillation?

ClinicalMetric currently tracks 41 actively recruiting clinical trials for atrial fibrillation, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 41. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for atrial fibrillation?

atrial fibrillation research spans Phase 2 (1 trial), Phase 3 (2 trials), Phase 4 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a atrial fibrillation clinical trial?

Eligibility criteria for atrial fibrillation trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 2

Phase 3

Phase 4

Top Sponsors

The Cleveland Clinic 2 trials

Imperial College London 2 trials

National Institute of Cardiology, Warsaw, Poland 2 trials

Yuehui Yin 1 trial

Fundación EPIC 1 trial

atrial fibrillation

Frequently Asked Questions — atrial fibrillation Clinical Trials

Recruiting Clinical Trials

Stepwise Strategy for Treatment of Atrialfibrillation Substrate Study

Safety and Effectiveness of Short-Term Single AntiPlatelet Therapy After Left Atrial Appendage Closure With the LAmbre Device in Patients With Nonvalvular Atrial Fibrillation: A Multinational Real-world Registry

Structured Testing and Treatment for Obstructive Sleep Apnea in Patients With Atrial Fibrillation

Quantitative Superior Vena Cava Isolation in Addition to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation

Long-Term Evaluation of TAILORED Vs Anatomical Ablation Strategy for Persistent Atrial Fibrillation

Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice

Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation

Post Intensive Care Unit Atrial Fibrillation

Feasibility Study of the FARAFLEX Mapping and PFA System

Coronary Computed Tomography AngioGraphy Prior to Catheter Ablation in Patients With Atrial FIBrillation

Austrian Left Atrial Appendage Closure Registry

Shock Energy for Electrical Cardioversion of Persistent Atrial Fibrillation

A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

OSA and CV Outcomes in Patients With High Risk AF

Surveillance Trial of the Apple Watch in Reliable Burden Assessment in Unseen Recurrence of Surgically Treated AF

BIO|CONCEPT.BIOMONITOR-HF Collect Clinical Data From Heart Failure Patients Using BIOMONITOR Devices With a Study Specific Research Software

Same-Day Discharge Versus Overnight Stay Following Pulmonary Vein Isolation for Atrial Fibrillation

Anteroposterior Versus Anterolateral Electrode Position for Electrical Cardioversion of Atrial Fibrillation

Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation

The Role of Right Atrial Ectopy Triggering Ganglionated Plexuses in AF

Registry of Multicenter Brain-Heart Comorbidity in China

Ablation of Focal Activation in Atrial Fibrillation

Atrial Fibrillation at the Viennese University Emergency Department

Development of CIRC Technologies

Deliver mOre aPplications for More Durable Pulmonary Vein IsOlation

Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure

Mechanisms for Atrial Fibrillation in Obstructive Sleep Apnea

RAFT - Pace &Ablate

Cerebral Protection in Transcatheter Left Atrial Appendage Occlusion

Anatomical Navigation for Guided Electrophysiology in AFL and AFib

The Role of hs Troponin I and NT-proBNP in Predicting Atrial Fibrillation in Patients With Permanent Pacemakers

SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF

Tracking Atrial Fibrillation After Intensive Care Admission

Rate or Rhythm Control in CRT: the RHYTHMIC Study

Acute Responses to Exercise in Females and Males With Symptomatic Atrial Fibrillation

Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients

AF Ablation With High Power Short Duration RF

Consistency of LGE-MRI Fibrosis and EAM Low-voltage Area